BioSpace News Archive

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms, is pleased to announce that the BAMS™ assay to detect the SARS-CoV-2 virus has been launched as a research kit 1 by its partner Adeptrix (Beverly, M

Project: AI based Assay Development for carbapenem-resistance based on porin loss and efflux pump overexpression in G ram-negative bacteria Project is part of the Research Campus Infecto G nostics and includes project partners at the University Hospital Jena, Institute for Infectious Diseases and Infection Contro l GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 30, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the pow

Healthcare providers across the United States can now access three different test options from Quest Diagnostics (NYSE: DGX) to aid the diagnosis of COVID-19 and differentiate it from o

iScience review paper details use of amino acids in medicine Axcella focused on designing novel EMM compositions with the potential to tackle complex diseases; plans to advance lead candidates into later-stage clinical trials CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) com

BIONIK Laboratories Announces Sale of New InMotion ® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology VA-funded center purchases second InMotion ® ARM/HAND interactive therapy system to test new approaches for restoring physical function of veterans with neurologic disease or injury TORONTO & BOSTON--( BUSINESS WIRE )-- BIONIK Laboratories Corp . (OTCQB:BNKL) (“BIONIK” or

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) 2020 Virtual Congress. The SRK-015 clinical development poster will showcase previously presented data from the Phase 1 healthy volunteer trial, as well as baselin

The American Foundation for the Blind announced the release of the Flatten Inaccessibility research report, the culmination of survey findings from 1,921 U.S. participants who are blind or have low vision.

SB-001, a gene therapy expressing feline erythropoietin (fEPO), demonstrates clinically relevant hematocrit improvements in end-stage anemia patients and improved quality of life scores

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Ohio Department of Rehabilitation and Correction (“ODRC”) has selected Fulgent Genetics for their COVID-19 testing needs. The Ohio Department of Rehabilitation and Correction will leverage Fulgent’s RT-PCR testing capabilities and En

Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time In CDD patients, median motor seizure frequency reduction was 24% in the ARCADE study, increasing to a 50% reduction in ENDYMION long-term extension study Clinical Global Impression of Change (CGI-C) and Caregiver Global Impression of Change (Care GI-C) suggest improvements beyond